![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Fagron Sterile Services Recalls Syringes After Labelling Gaffe
Fagron Sterile Services Recalls Syringes After Labelling Gaffe
![Recall stamp](https://www.fdanews.com/ext/resources/test/Device_Images5/Recall_Stamp.gif?t=1631569013&width=430)
July 5, 2018
Fagron Sterile Services recalled two lots of its Neostigmine syringes after a customer discovered that some of the syringes were incorrectly labeled at lower doses.
Neostigmine overdoses can cause a range of symptoms from nausea to death. So far, no adverse reactions have been reported, the company said.
The product is used to treat myasthenia gravis, an autoimmune disorder, and as a post-operative drug to help treat or prevent distention or urinary retention as well as the side effects from non-depolarizing neuromuscular blocking agents.
Upcoming Events
-
21Oct